Since the start of the second quarter, four of the five biotech ETFs have seen combined outflows of over $466 million with only the First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT) gaining new cash. [Biotech ETF at a Pivotal Point]
XLV and VHT have lost a combined $366 million this quarter.
However, the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) and the SPDR S&P Biotech ETF (NYSEArca: XBI) are up 6.4% and 14.3%, respectively, in the past month. Biotech stocks account for almost 19% of XLV’s weight and 20% of VHT.
Vanguard Health Care ETF
